Hedera Dx, a techbio company based in Switzerland, has secured €15 million in Series A funding to improve cancer care access. Investors led by Vsquared Ventures and Tesi support the company's efforts to overcome barriers in patient access to targeted therapies. By integrating diagnostics and real-world data, Hedera aims to be a leader in precision oncology outside the US. Their innovative liquid biopsies have already been implemented in 11 European nations, demonstrating a commitment to accessible cancer treatments through advanced technology and industry experience.
Hedera Dx is addressing a critical gap in global oncology care. Their approach improves hospital testing, increasing patient access to targeted therapies.
Hedera Dx's combination of diagnostics and real-world data positions them as leaders in precision oncology, improving healthcare systems outside the US.
Our goal is to build the infrastructure that enables precision cancer care to be accessible to every patient, overcoming current structural barriers.
The funding will help us tackle the limitations that currently restrict patient access to vital targeted cancer therapies.
Collection
[
|
...
]